

January 30, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Outcome of Board Meeting held on January 30, 2025

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. January 30, 2025 inter-alia approved/ took note the following(s):

Financial Results

1. Approved Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Nine Months ended December 31, 2024.

A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report(s) issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations are attached herewith as **Annexure- A**.

Interim Dividend

2. Approved declaration of 3rd Interim Dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the FY 2024-25. The record date for the purpose of payment of 3rd Interim Dividend shall be February 05, 2025.

The 3rd Interim Dividend will be dispatched/ credited within 30 days of the declaration.

Voluntary Liquidation of Suburban Diagnostics (India) Pvt. Ltd. (Wholly Owned Subsidiary)

3. Took note of approval accorded by Board of Directors of Suburban Diagnostics (India) Pvt. Ltd. (hereinafter referred to as “Suburban”), Wholly Owned Subsidiary of the Company for voluntary liquidation of Suburban and accordingly have granted their in-principle approval for expeditious consolidation of its business with the Company on a going concern basis, subject to compliance of applicable laws.

The said voluntary liquidation will lead to streamlining the structure and reduction in administrative overheads by reducing the number of entities in the group.

The requisite disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is attached herewith as **Annexure-B**

Others

4. Approved the Notice of Postal Ballot for seeking approval of the Members for Payment of Commission to Non-Executive Directors including Independent Directors.

Postal Ballot Notice shall be sent to the Members in due course and the same shall also be filed with the Stock Exchange(s).

5. Approved authorization to the following officials of the Company for determining materiality of an event or information under Regulation 30 of Listing Regulations, which shall be effective from April 01, 2025:

Name and Designation	Contact Details
(Hony) Brig. Dr. Arvind Lal, Executive Chairman	Dr. Lal PathLabs Limited 12th Floor, Tower B, SAS Tower Medicity, Sector-38 Gurugram - 122001 Email: cs@lalpathlabs.com Phone: 0124-3016500
Mr. Shankha Banerjee, Chief Executive Officer (CEO)	
Mr. Ved Prakash Goel, Group CFO & CEO – International Business	

Based on the decision of the above-named officials, the Compliance Officer of the Company shall be responsible for making necessary disclosure to the Stock Exchange(s) and his contact details are given hereunder:

Dr. Lal PathLabs Limited,
12th Floor, Tower B, SAS Tower, Medicity,
Sector-38, Gurugram - 122001
Email: cs@lalpathlabs.com
Phone: 0124-3016500

6. Approved amendment in Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (“Code”). The Amended Code is attached herewith as **Annexure- C**.

The Board Meeting commenced at 10:00 A.M (IST) and concluded at 1:32 P.M (IST)

We request you to please take the same on record.

Thanking You,
Yours Faithfully,
For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Dr. LAL PATHLABS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Dr. Lal PathLabs Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2024 ('the Statement'), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a) Dr. Lal PathLabs Limited, the Parent company
 - b) Paliwal Diagnostics Private Limited, a subsidiary company
 - c) Dr. Lal PathLabs Nepal Private Limited, a subsidiary company
 - d) Dr. Lal PathLabs Bangladesh Private Limited, a subsidiary company
 - e) Dr. Lal Ventures Private Limited, a subsidiary company
 - f) PathLabs Unifiers Private Limited, a subsidiary company
 - g) Dr. Lal PathLabs Kenya Private Limited, a subsidiary company (dissolved vide date of publication of gazette notification w.e.f. September 13, 2024)
 - h) Suburban Diagnostics (India) Private Limited, a subsidiary company
 - i) Centrapath Labs Private Limited, a step-down subsidiary company
 - j) APRL PathLabs Private Limited, a step-down subsidiary company
 - k) Chanre Laboratory Private Limited, a step-down subsidiary company



5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Consolidated Unaudited Financial Results include the interim unaudited financial results and other unaudited financial information of three subsidiary companies which have not been reviewed by their auditors and have been approved and furnished to us by the Management, whose interim financial results reflect total revenue of Rupees 44.72 Million and Rupees 138.27 Million for the quarter and nine months ended December 31, 2024 respectively, total loss after tax of Rupees 2.70 Million and Rupees 4.96 Million for the quarter and nine months ended December 31, 2024 respectively, and total comprehensive loss of Rupees 2.42 Million and Rupees 4.43 Million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such interim unaudited financial results and other unaudited financial information certified by the Management. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matter stated in para 6 above is not modified with respect to our reliance on the financial results certified by the Management.


For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)




RASHIM TANDON

Partner
Membership No: 95540
(UDIN: 25095540BMOXHV6328)

Place: Gurugram
Date: January 30, 2025



Dr. Lal PathLabs Limited
CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana
Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December, 2024

(Rs. in million except as stated)

Particulars	3 months ended 31 December, 2024	Preceding 3 months ended 30 September, 2024	Corresponding 3 months ended in previous year 31 December, 2023	Year to date figures for the current period ended 31 December, 2024	Year to date figures for the previous period ended 31 December, 2023	Previous year ended 31 March, 2024
	(Unaudited)	(Unaudited)	(see note vii) (Unaudited)	(Unaudited)	(see note vii) (Unaudited)	(see note vii) (Audited)
1 Income						
(a) Revenue from operations	5,967	6,602	5,389	18,588	16,812	22,266
(b) Other income	251	219	183	676	508	692
Total income	6,218	6,821	5,572	19,264	17,320	22,958
2 Expenses						
(a) Cost of materials consumed	1,170	1,273	1,070	3,637	3,425	4,514
(b) Employee benefits expense	1,264	1,240	1,090	3,670	3,191	4,245
(c) Finance costs	53	60	70	173	228	294
(d) Depreciation and amortisation expense	355	353	360	1,055	1,070	1,436
(e) Fees to collection centers/channel partners	867	937	777	2,641	2,374	3,130
(f) Other expenses	1,126	1,127	1,046	3,375	3,176	4,284
Total expenses	4,835	4,990	4,413	14,551	13,464	17,903
3 Profit before tax	1,383	1,831	1,159	4,713	3,856	5,055
4 Tax expense						
(a) Current tax	395	484	344	1,327	1,154	1,480
(b) Deferred tax	7	39	(7)	19	(63)	(48)
Total tax expense	402	523	337	1,346	1,091	1,432
5 Profit for the period (A)	981	1,308	822	3,367	2,765	3,623
6 Other comprehensive income/(loss)						
Items that will not be reclassified to profit or loss:						
-Remeasurement of the defined benefit obligations	(1)	(10)	4	(13)	8	(5)
-Income tax in relation to the items that will not be reclassified to profit or loss	(1)	3	(1)	2	(2)	1
Items that may be reclassified to profit or loss:						
-Exchange differences on translation of foreign operations	1	(1)	(1)	1	(3)	(2)
Total other comprehensive income/(loss) (B)	(1)	(8)	2	(10)	3	(6)
7 Total comprehensive income (A+B)	980	1,300	824	3,357	2,768	3,617
Profit for the period attributable to:						
Owners of the Company	967	1,292	813	3,323	2,732	3,577
Non-controlling interest	14	16	9	44	33	46
	981	1,308	822	3,367	2,765	3,623
Other comprehensive income/(loss) for the period attributable to:						
Owners of the Company	(1)	(8)	2	(10)	3	(6)
Non-controlling interest	-	-	-	-	-	-
	(1)	(8)	2	(10)	3	(6)
Total comprehensive income for the period attributable to:						
Owners of the Company	966	1,284	815	3,313	2,735	3,572
Non-controlling interest	14	16	9	44	33	45
	980	1,300	824	3,357	2,768	3,617
8 Paid-up equity share capital (Face value of Rs. 10 per share)	836	836	835	836	835	835
9 Other equity						17,658
10 Earnings per share (Rs.)						
(Face value of Rs. 10 per share)(not annualised)						
-Basic	11.60	15.52	9.77	39.91	32.88	43.05
-Diluted	11.58	15.48	9.76	39.83	32.81	42.98

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2024 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. During the nine months ended 31 December 2024, the Parent Company has issued 15,983 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options.
- Further, during the nine months ended 31 December 2024, the Parent Company has issued 93,900 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- v. The Board of Directors of the Parent Company have approved third interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2025.
- The Board of Directors of the Parent Company had approved second interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 23 October, 2024 which was paid on 16 November 2024.
- The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 7 August, 2024 which was paid on 29 August, 2024.
- The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2024. The same was approved by the shareholders in the Annual General Meeting held on 29 June, 2024 and this was paid on 4 July, 2024.
- vi. During the nine month ended 31 December 2024, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, has been dissolved and its name has been struck off, with effect from the date of publication of gazette notification dated September 13, 2024.
- vii. The Hon'ble Allahabad Bench of the National Company Law Tribunal ("Hon'ble Tribunal" or 'NCLT') sanctioned the Scheme of Amalgamation ("Scheme") between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024 respectively.
- The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.
- Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.
- Accordingly, the results for the quarter and nine months ended 31 December 2023 and year ended 31 March 2024, have been restated to give effect of the amalgamation.
- viii. The Board of Directors of the Parent Company at their meeting held on 30 January, 2025 took note of in-principle approval accorded by the Board of Suburban Diagnostics (India) Private Limited ("Suburban"), a wholly owned subsidiary of the Company for voluntary liquidation of Suburban.
- The Board of the Parent Company has accorded in-principle approval for expeditious consolidation of Suburban's business with the Company on a going concern basis. Upon Voluntary liquidation of Suburban, existing business of Suburban will be distributed to the Company (only shareholder of Suburban) as a going concern. As on date the said transaction is subject to necessary approvals and yet to be completed.
- ix. As at 31st December, 2024, the Parent company has the following subsidiaries:
- | <u>Subsidiaries</u> | <u>Step-down subsidiaries</u> | <u>JV/Associate Company- Nil</u> |
|--|-----------------------------------|----------------------------------|
| Paliwal Diagnostics Private Limited | Centrapath Labs Private Limited | |
| Dr. Lal PathLabs Nepal Private Limited | APRL PathLabs Private Limited | |
| Dr. Lal PathLabs Bangladesh Private Limited | Chanre Laboratory Private Limited | |
| Dr. Lal Ventures Private Limited | | |
| PathLabs Unifiers Private Limited | | |
| Suburban Diagnostics (India) Private Limited | | |
- x. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

Place: Gurugram
Date: 30 January, 2025

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'y) Brig. Dr. Arvind Lal
Executive Chairman

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Dr. LAL PATHLABS LIMITED


1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Dr. Lal PathLabs Limited ("the Company"), for the quarter and nine month ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)

Place: Gurugram
Date: January 30, 2025




RASHIM TANDON
Partner
Membership No: 95540
(UDIN: 25095540BMOXHU2385)



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December, 2024

(Rs. in million except as stated)

Particulars	3 months ended 31 December, 2024	Preceding 3 months ended 30 September, 2024	Corresponding 3 months ended in previous year 31 December, 2023	Year to date figures for the current period ended 31 December, 2024	Year to date figures for the previous period ended 31 December, 2023	Previous year ended 31 March, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income						
(a) Revenue from operations	5,281	5,839	4,760	16,465	14,878	19,668
(b) Other income	295	220	151	803	442	601
Total income	5,576	6,059	4,911	17,268	15,320	20,269
2 Expenses						
(a) Cost of materials consumed	1,019	1,100	927	3,168	2,960	3,908
(b) Employee benefits expense	1,099	1,074	934	3,181	2,733	3,636
(c) Finance costs	48	50	65	153	209	268
(d) Depreciation and amortisation expense	189	182	192	549	567	765
(e) Fees to collection centers/channel partners	812	879	727	2,479	2,241	2,948
(f) Other expenses	897	941	871	2,783	2,655	3,584
Total expenses	4,064	4,226	3,716	12,313	11,365	15,109
3 Profit before tax	1,512	1,833	1,195	4,955	3,955	5,160
4 Tax expense						
(a) Current tax	365	442	319	1,212	1,076	1,376
(b) Deferred tax	2	39	(7)	17	(70)	(60)
Total tax expense	367	481	312	1,229	1,006	1,316
5 Profit for the period (A)	1,145	1,352	883	3,726	2,949	3,844
6 Other comprehensive income/(loss)						
Items that will not be reclassified to profit or loss	(2)	(14)	1	(18)	2	(4)
-Remeasurement of the defined benefit obligations	-	3	(1)	4	(1)	1
-Income tax in relation to the items that will not be reclassified to profit or loss	-	3	(1)	4	(1)	1
Total other comprehensive income/(loss) (B)	(2)	(11)	-	(14)	1	(3)
7 Total comprehensive income (A+B)	1,143	1,341	883	3,712	2,950	3,841
8 Paid-up equity share capital (Face value of Rs. 10 per share)	836	836	835	836	835	835
9 Other equity						18,162
10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised)						
- Basic	13.74	16.24	10.78	44.75	35.50	46.25
- Diluted	13.71	16.20	10.75	44.66	35.42	46.18

Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended 31 December, 2024 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Further, during the nine months ended 31 December 2024, the Company has issued 93,900 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- iii. During the nine months ended 31 December 2024, the Company has issued 15,983 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options.

The Board of Directors of the Company have approved third interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2025.


The Board of Directors of the Company had approved second interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 23 October, 2024 which was paid on 16 November, 2024.

The Board of Directors of the Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 7 August, 2024 which was paid on 29 August, 2024.

The Board of Directors of the Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2024. The same was approved by the shareholders in the Annual General Meeting held on 29 June, 2024 and this was paid on 4 July, 2024.
- iv. During the nine months ended 31 December 2024, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, has been dissolved and its name has been struck off, with effect from the date of publication of gazette notification dated September 13, 2024.
- v. The Board of Directors of the Company at their meeting held on 30 January, 2025 took note of in-principle approval accorded by the Board of Suburban Diagnostics (India) Private Limited ("Suburban"), a wholly owned subsidiary of the Company for voluntary liquidation of Suburban.

The Board of the Company has accorded in-principle approval for expeditious consolidation of Suburban's business with the Company on a going concern basis. Upon Voluntary liquidation of Suburban, existing business of Suburban will be distributed to the Company (only shareholder of Suburban) as a going concern. As on date the said transaction is subject to necessary approvals and yet to be completed.
- vi. During the nine months ended 31 December 2024, the Company has made further investment of INR 6 million in its wholly owned subsidiary, Suburban Diagnostics (India) Private Limited (SDIPL) through purchase of ESOPs.
- vii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited



(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 30 January, 2025

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

S. No.	Particulars	Details									
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Financial Parameters of Suburban Diagnostics (India) Pvt. Ltd. ("Suburban") as on March 31, 2024: <table border="1"> <thead> <tr> <th>Particulars</th> <th>Amount (In Cr.)</th> <th>% of consolidation</th> </tr> </thead> <tbody> <tr> <td>Turnover</td> <td>INR 164.03</td> <td>7.37%</td> </tr> <tr> <td>Net worth</td> <td>INR 126.62</td> <td>7.05%</td> </tr> </tbody> </table>	Particulars	Amount (In Cr.)	% of consolidation	Turnover	INR 164.03	7.37%	Net worth	INR 126.62	7.05%
Particulars	Amount (In Cr.)	% of consolidation									
Turnover	INR 164.03	7.37%									
Net worth	INR 126.62	7.05%									
2	Date on which the agreement for sale has been entered into	Not Applicable									
3	The expected date of completion of sale/ disposal	The process of voluntary liquidation of Suburban as a solvent Company will be completed subject to requisite statutory and regulatory approvals.									
4	Consideration received from such sale/ disposal	The entire business of Suburban on a going concern basis.									
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Not Applicable									
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length	Not Applicable									
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable Voluntary liquidation is not a sale of undertaking.									
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable Voluntary liquidation is not a slump sale.									

Dr. Lal PathLabs Limited

Last amended by the
Board of Directors
on January 30, 2025

Corporate Identity Number: L74899DL1995PLC065388

Regd. Office: Block E, Sector - 18, Rohini, New Delhi – 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Gurugram - 122001

Website: www.lalpathlabs.com, Phone: +91 124 3016500 | Fax: +91 124 4234468

CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURES OF UNPUBLISHED PRICE SENSITIVE INFORMATION

[Under Regulation 8(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015]

1. Introduction

In terms of Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (“Regulations”), Dr. Lal PathLabs Limited required to formulate a Code of Practices and Procedures for Fair Disclosures of Unpublished Price Sensitive Information (“Code”).

2. Objective of the Code

The Company endeavors to preserve the confidentiality of Unpublished Price Sensitive Information (“UPSI”) and to prevent its misuse. To achieve this objective and in compliance with the aforesaid regulations, the Board of Directors have adopted this code.

The Code ensures timely and adequate disclosure of UPSI which could impact the prices of its securities and maintains the uniformity, transparency and fairness in dealing with all its stakeholders.

3. Definitions

- a. **“Chief Investors Relations Officer” (“CIRO”)** means the Company Secretary & Compliance Officer of the Company.
- b. **“Company”** means Dr. Lal PathLabs Limited (hereinafter referred as “the Company”)
- c. **“Compliance Officer”** for the purpose of these regulations means the Company Secretary of the Company.
- d. **“Mainstream Media”** shall include print or electronic mode (as amended by SEBI from time to time) of the following:
 - i. Newspapers registered with the Registrar of Newspapers for India;
 - ii. News Channels permitted by Ministry of Information and Broadcasting under Government of India;
 - iii. Content published by the publisher of news and current affairs content as defined under the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021; and
 - iv. Newspapers or news channels or news and current affairs content similarly registered or permitted or regulated, as the case may be, in jurisdictions outside India.
- e. **“Unpublished price sensitive information” (“UPSI”)** means any information, relating to a Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and

Dr. Lal PathLabs Limited

shall ordinarily including but not restricted to, information relating to Financial Results, Dividends, change in Capital Structure, Mergers, De-mergers, Acquisitions, Delisting, Disposals and Expansion of Business and such other transactions, changes in Key Managerial Personnel and other material event(s) as may be specified under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended from time to time.

The word and expression used and not defined in this code but defined in SEBI (Prohibition of Insider Trading) Regulations, 2015, SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Securities Contracts (Regulation) Act, 1956, The Depositories Act, 1996 and Companies Act, 2013 shall have the meaning assigned to them in those legislations.

The Company will adhere to the following guidelines so as to ensure fair disclosure of events and occurrence(s) that may impact price of its securities.

4. Norms for disclosure of UPSI

a. Prompt public disclosure of UPSI

UPSI shall be disclosed by the Company to the Stock Exchange(s) promptly when credible & concrete information is available for making the same generally available and shall also be uploaded on the Company's official website (www.lalpathlabs.com), in compliance of regulatory requirements.

b. Uniform and Universal dissemination of UPSI

The disclosure of UPSI shall be on a continuous, immediate, uniform, universally disseminated and due care will be taken to avoid selective disclosure.

c. Overseeing and coordinating disclosure(s)

The CIRO shall oversee corporate disclosures and deal with dissemination of information and disclosure of UPSI.

The CIRO shall be responsible for ensuring that the Company complies with continuous disclosure requirements and for overseeing and coordinating disclosure of UPSI to Stock Exchanges, on the website of the Company and to the media, if required.

If any information is accidentally disclosed without prior approval of CIRO the person responsible may inform the CIRO immediately. In such event of inadvertent disclosure of UPSI, the CIRO shall take prompt action to ensure such information is generally available.

In addition to the CIRO, the following persons are also authorized to communicate with the Investors/ media:

Dr. Lal PathLabs Limited

- i. Chairman
- ii. Managing Director
- iii. Executive Director(s)
- iv. CEO&
- v. CFO

d. Responding to market rumours

The CIRO shall respond to any queries on news reports and requests for verification of market rumours by regulatory authorities including Stock Exchanges on behalf of the Company.

The CIRO in consultation with Managing Director/ Chief Executive Officer and Chief Financial Officer shall provide proper and equitable response i.e. Confirm/ Deny/ Clarify on reported event or information in the mainstream media, as required under the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015.

5. Process of disseminating information in order to make the UPSI generally available

- Disclosure/dissemination of information may be done through various media so as to achieve maximum reach and quick dissemination.
- The website of the Company may provide a means of giving investors a direct access to analyst briefing material, significant background information and questions & answers.

6. Manner of dealing with analyst and research personnel

- a. **Only Public information to be provided** – A Company shall provide only public information to the analyst/research persons/large investors like institutions.
- b. **Recording of discussion** - In order to avoid misquoting or misrepresentation, it is desirable that at least two Company's representatives be present at meetings with analysts, brokers or institutional investors. The Company shall adopt best practices to make transcripts or records of proceedings of such meetings available on the website of the Company to ensure official confirmation and documentation of disclosures made.
- c. **Handling of unanticipated questions** –The Company should be careful when dealing with analysts' questions that raise issues outside the intended scope of discussion. Unanticipated questions may be taken on notice and a considered response given later. If the answer includes UPSI, a public disclosure, if considered appropriate, should be made before responding.

7. UPSI on Need-to-Know basis

UPSI shall be handled on a "need to know" basis i.e. it shall be disclosed only to those where such communication is in furtherance of legitimate purposes, performance of duties or discharge of legal obligations.

Dr. Lal PathLabs Limited

8. Policy for Determination of Legitimate Purposes

“Legitimate Purpose” shall include sharing of unpublished price sensitive information in the ordinary course of business by an insider with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants, provided that such sharing has not been carried out to evade or circumvent the prohibitions of these regulations.

Any person in receipt of unpublished price sensitive information pursuant to a “Legitimate Purpose” shall be considered an “insider” for purposes of these regulations and due notice shall be given to such persons to maintain confidentiality of such unpublished price sensitive information in compliance with these regulations.

A structured digital database shall be maintained containing the nature of unpublished price sensitive information and the names of such persons who have shared the information and also the names of such persons or entities as the case may be with whom information is shared for legitimate purpose along with the Permanent Account Number or any other identifier authorized by law where Permanent Account Number is not available. Such database shall not be outsourced and shall be maintained internally with adequate internal controls and checks such as time stamping and audit trails to ensure non-tampering of the database.

The Company shall ensure that the structured digital database is preserved for a period of not less than eight years after completion of the relevant transactions and in the event of receipt of any information from SEBI regarding any investigation or enforcement proceedings, the relevant information in the structured digital database shall be preserved till the completion of such proceedings.

Following factors must be satisfied while determining what constitutes a legitimate purpose

- i. Must be shared in the ordinary of course of business or for Corporate Purpose;
- ii. Required to be done in furtherance of fiduciary duties or in fulfillment of any statutory or contractual obligation;
- iii. The action is executed in a manner which is considered as fair and transparent; and
- iv. Information shared is in the interest of Company and should not result into a personal benefit to the Insider

9. Disclosure of Code on Public Domain

This Code and any amendment thereof shall be published on the Company’s website www.lalpathlabs.com.

10. Amendments to the Code

The Board of Directors may review or amend this code, in whole or in part, from time to time, as per the requirements of the Companies Act, 2013 or SEBI (Prohibition of Insider Trading) Regulations, 2015 or any other enactments/rules/amendments as may be made applicable.

This Code is in addition to and not in derogation of the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015. In case of any inconsistency, the provisions of the Regulations shall prevail.